

Boost Seminar  
December 6th 2017

Navigating the Shifting Currents of U.S. Biotech and Pharmaceutical Patent Law



**Margaret (Peg) Bolce Brivanlou, PhD**

Partner

Intellectual Property Counseling/Intellectual Property,  
Patent, Trademark and Copyright Litigation  
King & Spalding

Peg Brivanlou specializes in patent prosecution, client counseling, due diligence and patent litigation. As a Partner in our Intellectual Property, Patent, Trademark and Copyright Litigation practice, Peg represents clients in the biotechnology and pharmaceutical industries, and investment funds in a variety of intellectual property matters.

With a focus on biologics and small molecule therapeutics, Peg counsels clients regarding immunotherapeutics, cell-based assays and therapies, genomics, bioinformatics, vaccines and small molecule pharmaceuticals. She is experienced in developing patent portfolios, particularly relating to biologics, antibody therapeutics and diagnostics. She also conducts patent invalidity, freedom-to-operate analyses and pre-litigation investigations, including for pre-Hatch-Waxman litigation.

In addition, Peg represents clients on the intellectual property aspects of a wide range of transactions, from technology transfer and out-licensing to multi-million-dollar asset purchases and financings. She conducts due diligence, and negotiates licensing and purchase agreements as well as disclosure documents in connection with public and private financings.

Presenting to conferences and in-house counsel, Peg is a frequent speaker on a variety of patent issues.

# Credentials

## EDUCATION

A.B., Cornell University, magna cum laude

J.D., Harvard University, cum laude

Ph.D., University of California-Berkeley

## ADMISSIONS

U.S. Patent and Trademark Office

New York

## ASSOCIATIONS

New York State Bar Association

New York Intellectual Property Law Association

## LANGUAGES

French

# Matters

- Primary intellectual property counsel to **a private investment fund** in connection with significant royalty stream acquisitions and financings.
- Represents **a private biotechnology company** in developing patent portfolio relating to immunotherapeutics.
- Represents **a major pharmaceutical company** in patent prosecution and counseling relating to small molecule pharmaceuticals, including approved products and products in late stage clinical trials, for cardiovascular indications.
- Represents **a foreign pharmaceutical firm** in patent prosecution and counseling relating to RNAi therapeutics.
- Represented **a major pharmaceutical company and private biotechnology companies** in administrative and court challenges against the USPTO relating to patent term adjustment calculations.

# Insights

## ARTICLE

2017-06-15

High Court's Superficial Analysis In Biosimilars Ruling

## CLIENT ALERT

2017-06-13

The Age of Competition

## ARTICLE

2017-06-12

Clarity From Chaos

## THOUGHT LEADERSHIP

2017-02-27

U.S. PTO Highlights Patent Paper Co-Authored by Kenneth Sonnenfeld

**CLIENT ALERT**

2016-05-11

Patentable Subject Matter in the Life Sciences: New USPTO Guidance Impacts Diagnostics Methods and Natural Products

**THOUGHT LEADERSHIP**

2016-03-06

Peg Brivanlou to Co-Host Women in Licensing-DC Meeting

## Events

**CONFERENCE**

2017-09-07

Medical Device Summit 2017

## CONFERENCE

2017-06-08

Managing IP's International Women's Leadership Forum

## CONFERENCE

2016-11-15

9th Annual King & Spalding Pharmaceutical University

## CONFERENCE

2015-10-28

ChIPs Women in IP Global Summit 2015, Tenth Anniversary Celebration

## WEBINAR

2015-09-10

All Trees, No Forest? Making Sense of Recent Developments in Life Sciences Patent Law

## News

### CASES & DEALS

2017-08-09

King & Spalding Advises Dermira on Worldwide Licensing Agreement with Roche

### RECOGNITION

2017-06-20

Chambers Honors King & Spalding's Women in IP Group With 'Most Innovative Women's Networking Group' Award